Patients with ANCA-associated vasculitis receiving low glucocorticoid doses as per the PEXIVAS trial faced an increased risk ...

Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including ...

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

SC291, a hypoimmune-modified CD19-directed allogeneic CAR T therapy, is being evaluated in Sana’s GLEAM trial in patients with B-cell mediated autoimmune diseases including lupus nephritis, extrarenal ...

Learn how reduced-dose steroids affect relapse and progression in ANCA-associated vasculitis patients, especially those on ...

3 Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France ...